Last reviewed · How we verify
Chemical Denervation with Absolute Alcohol
At a glance
| Generic name | Chemical Denervation with Absolute Alcohol |
|---|---|
| Sponsor | Federal University of São Paulo |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Back pain
- Headache
- Post procedural haematoma
- Glomerular filtration rate decreased
- Hypertension
- Oedema peripheral
- Nasopharyngitis
- Blood pressure increased
- Hypertensive crisis
- Tachycardia
- COVID-19
- Arthralgia
Key clinical trials
- Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR) (PHASE3)
- The TARGET BP OFF-MED Trial (PHASE2)
- Comparison of Denervation Techniques for the Treatment of Knee Osteoarthritis: Continuous Ablative Radiofrequency Vs. Chemical Denervation with Absolute Alcohol (NA)
- A Nerve Block Therapy for Bulbar Palsy Pharyngeal Dysphagia (NA)
- TARGET BP I Clinical Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: